文章基本信息

标题：Management of cytomegalovirus corneal endotheliitis
本地全文：下载
作者：Angela H. Y. Wong ; Wee Nie Kua ; Alvin L. Young 等
期刊名称：Eye and Vision
印刷版ISSN：2326-0254
出版年度：2021
卷号：8
期号：1
页码：1-13
DOI：10.1186/s40662-020-00226-y
出版社：BioMed Central
摘要：Cytomegalovirus (CMV) can manifest as corneal endotheliitis in immunocompetent individuals. Early diagnosis is prudent to prevent endothelial cell loss, which could ultimately lead to corneal decompensation. CMV DNA was first detected in an eye with corneal endotheliitis in 2006; since then, clinical evidence from numerous case reports and case series have accumulated. In this narrative review, we identified several drugs, including ganciclovir, valganciclovir, and their combination in oral, intravenous, intravitreal, and topical forms in different concentrations, together with the judicious use of topical steroids, have reported variable success. There has yet to be any prospective comparative study evaluating the efficacy and safety of these assorted forms of treatment; clinical evidence is based on case reports and case series. CMV endotheliitis presenting with corneal edema can masquerade as other corneal diseases and thus poses a great challenge especially in post-keratoplasty eyes. Heightened awareness is needed before and after keratoplasty to start prompt prophylaxis and treatment. There is no consensus on the management of CMV endotheliitis. Further studies are much needed to elucidate the optimal treatment modality, regime, and duration in the treatment and prophylaxis of CMV endotheliitis.
关键词：Cytomegalovirus ; CMV ; Endotheliitis ; Keratoplasty ; Corneal transplant ; Cornea